The HSPG2 Knockout HT29 Polyclonal Cells represent a genetically diverse population of HT29 human colorectal adenocarcinoma cells engineered via CRISPR/Cas9 to disrupt the HSPG2 gene, which encodes the proteoglycan perlecan. Delivered as a polyclonal pool, this loss-of-function model circumvents clonal selection artifacts and enables robust investigation of perlecan biology in a heterogeneous cancer cell context. These cells are intended for advanced research into tumor biology, extracellular matrix dynamics, and growth factor signaling pathways.
The HT29 parental line originates from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female and displays adherent epithelial morphology with wild-type p53 and microsatellite stability. This well-characterized model forms polarized, mucin-secreting monolayers and is routinely employed in studies of intestinal epithelial function, colorectal cancer progression, and drug absorption, thereby providing a physiologically relevant host for gene knockout analysis.
Perlecan is a multifaceted heparan sulfate proteoglycan of basement membranes and ECM that coordinates cell behavior through structural and signaling interactions. It binds collagen IV, laminin, nidogen, and fibronectin while engaging integrins such as ??2??1 and ??v??3 to regulate adhesion and migration. As a co-receptor, perlecan presents growth factors??including FGF-2, VEGF, and PDGF??to their receptors, potentiating downstream ERK/MAPK, Akt/PKB, and FAK/Src cascades. Upstream regulators like TGF-??, EGF, and HIF-1?? influence perlecan expression, and its activity modulates downstream targets including ??-catenin, Rho GTPases, and matrix metalloproteinases.
In the colorectal cancer setting of HT29 cells, HSPG2 knockout disrupts perlecan??s structural and signaling functions. Loss of perlecan-mediated growth factor sequestration attenuates ERK/MAPK and Akt pathway activation, which are frequently hyperactivated in colorectal cancer, while impaired integrin engagement reduces FAK signaling, likely diminishing cellular migration and invasion. This polyclonal system thus provides a valuable tool for studying perlecan??s role in tumor microenvironment interactions and angiogenic signaling without the bias of clonal isolation.
Researchers can apply this knockout model in diverse assays, including tumor microenvironment co-cultures, Transwell migration and adhesion studies, phospho-signaling analysis of ERK and Akt, and in vitro angiogenesis tube formation. Transcriptomic or proteomic profiling can further elucidate perlecan-dependent networks. Additionally, the cells serve as a platform for evaluating drugs targeting heparan sulfate proteoglycans and for exploring perlecan-related disease mechanisms. For additional information or technical support, please contact Ascent Research.
